RESUMEN
CONTEXT: Treatment of pheochromocytoma and paraganglioma (PPGL) requires preintervention titration of alpha- and beta-adrenergic blockade, but patients may still be at risk for complications from catecholamine excess. Metyrosine decreases catecholamine production, making it an attractive therapeutic adjunct for select patients. EVIDENCE ACQUISITION: A systematic literature review was performed (Ovid Medline and Scopus databases) on December 17, 2019, including studies with humans and original data. Studies with 10 or more patients on metyrosine for PPGL were included. Studies were screened for overlapping populations, and the most comprehensive study was included. The references of included studies were reviewed for additional data. Patient data from our institution between 2000 and 2015 were also reviewed. EVIDENCE SYNTHESIS: Metyrosine is well tolerated when used for a short course and can improve intraoperative outcomes in PPGL. Metyrosine should be considered when a difficult PPGL resection is expected (eg, pericardiac paraganglioma, abdominal paraganglioma with great vessel involvement), a large release of catecholamines is anticipated (eg, ablative therapy, chemotherapy), or when standard alpha- and beta-adrenergic blockade are not tolerated or cannot adequately control hypertension. Side effects are generally mild and self-limited, with sedation in a majority of patients. Extrapyramidal side effects are rare but can limit use of metyrosine. Because of its expense and limited availability, metyrosine use should be carefully planned and timed in relation to surgery. CONCLUSIONS: Metyrosine is a safe addition to traditional alpha- and beta-adrenergic blockade and should be considered in those patients with PPGL at high risk for acute release of catecholamines.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/tratamiento farmacológico , Paraganglioma/tratamiento farmacológico , Feocromocitoma/tratamiento farmacológico , alfa-Metiltirosina/uso terapéutico , Neoplasias de las Glándulas Suprarrenales/complicaciones , Neoplasias de las Glándulas Suprarrenales/epidemiología , Neoplasias de las Glándulas Suprarrenales/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Combinada , Humanos , Hipertensión/tratamiento farmacológico , Hipertensión/epidemiología , Hipertensión/etiología , Paraganglioma/complicaciones , Paraganglioma/epidemiología , Paraganglioma/patología , Feocromocitoma/complicaciones , Feocromocitoma/epidemiología , Feocromocitoma/patología , alfa-Metiltirosina/efectos adversosRESUMEN
Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized the safety, tolerability, and efficacy of SMK Therapy in subjects with advanced metastatic cancer. Methods All subjects (n = 30) received SMK Therapy for an initial 6 week Cycle (5 days on, 2 off per week) and continued if well tolerated. Safety signals, clinical response, overall survival, progression free survival (PFS), and quality of life changes were assessed. Results The most common drug related adverse events were hyperpigmentation and rash. All drug related adverse events were mild to moderate in intensity. Following treatment with SMK Therapy, 4 subjects achieved complete response, 6 partial response, and 17 stable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (total clinical benefit 90%). Responses were observed within 6 weeks, and continued to improve, with 3 complete and 3 partial responders achieving best response after at least 3.2 months. Durable stable disease was observed, lasting a median duration of 11 months (range 1-31 months). Median overall survival for all subjects was 29.8 months, and median PFS was 13 months. Following 6 weeks of treatment, most (83.3%) subjects showed an improvement in Eastern Cooperative Oncology Group (ECOG) score and an improvement in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ 30) global health status (baseline 61.2 ± 25.0; end of Cycle 1 80.7 ± 14.7; n = 29; p < 0.001). Conclusions The results of this study support continued development of SM-88.
Asunto(s)
Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Melaninas/uso terapéutico , Neoplasias/tratamiento farmacológico , Fenitoína/uso terapéutico , Sirolimus/uso terapéutico , alfa-Metiltirosina/uso terapéutico , Anciano , Antineoplásicos/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Exantema/inducido químicamente , Femenino , Humanos , Hiperpigmentación/inducido químicamente , Masculino , Melaninas/efectos adversos , Persona de Mediana Edad , Neoplasias/mortalidad , Neoplasias/patología , Fenitoína/efectos adversos , Proyectos Piloto , Calidad de Vida , Sirolimus/efectos adversos , Análisis de Supervivencia , alfa-Metiltirosina/efectos adversosRESUMEN
We recently conducted an open-label phase I/II study to evaluate the efficacy and safety of preoperative and chronic treatment with metyrosine (an inhibitor of catecholamine synthesis) in pheochromocytoma/paraganglioma (PPGL) in Japan. We compared creatinine-corrected metanephrine fractions in spot urine and 24-hour urine samples (the current standard for the screening and diagnosis of PPGLs) from 16 patients to assess the therapeutic effect of metyrosine. Percent changes from baseline in urinary metanephrine (uMN) or normetanephrine (uNMN) were compared between spot and 24-hour urine samples. Mean percent changes in uMN or uNMN in spot and 24-hour urine were -26.36% and -29.27%, respectively. The difference in the percent change from baseline between uMN or uNMN in spot and 24-hour urine was small (-2.90%). The correlation coefficient was 0.87 for percent changes from baseline between uMN or uNMN measured in spot and 24-hour urine. The area under the receiver operator characteristic (ROC) curve of uMN or uNMN measured in spot urine vs. 24-hour urine (reference standard) to assess the efficacy of metyrosine treatment was 0.93. Correlations and ROCs between 24-hour urinary vanillylmandelic acid, adrenaline, and noradrenaline and 24-hour uMN or uNMN were similar to those between spot uMN or uNMN and 24-hour uMN or uNMN. No large difference was observed between spot and 24-hour urine for the assessment of metyrosine treatment by quantifying uMN or uNMN in Japanese patients with PPGLs. These results suggest that spot urine samples may be useful in assessing the therapeutic effect of metyrosine.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/orina , Metanefrina/orina , Paraganglioma/orina , Feocromocitoma/orina , alfa-Metiltirosina/uso terapéutico , Adolescente , Neoplasias de las Glándulas Suprarrenales/tratamiento farmacológico , Neoplasias de las Glándulas Suprarrenales/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Niño , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Normetanefrina/orina , Paraganglioma/tratamiento farmacológico , Paraganglioma/cirugía , Feocromocitoma/tratamiento farmacológico , Feocromocitoma/cirugía , Cuidados Preoperatorios/métodos , Curva ROC , Sensibilidad y Especificidad , alfa-Metiltirosina/administración & dosificación , alfa-Metiltirosina/efectos adversosRESUMEN
To assess the efficacy, safety, and pharmacokinetics of metyrosine (an inhibitor of catecholamine synthesis) in patients with pheochromocytoma/paraganglioma (PPGL), we conducted a prospective, multi-center, open-label study at 11 sites in Japan. We recruited PPGL patients aged ≥12 years requiring preoperative or chronic treatment, receiving α-blocker treatment, having baseline urinary metanephrine (uMN) or normetanephrine (uNMN) levels ≥3 times the upper limit of normal values, and having symptoms associated with excess catecholamine. Metyrosine treatment was started at 500 mg/day and modified according to dose-adjustment criteria up to 4,000 mg/day. The main outcome measure was the proportion of patients who achieved at least 50% reduction in uMN or uNMN levels from baseline. Sixteen patients (11 males/5 females) aged 12-86 years participated. After 12 weeks of treatment and at the last evaluation of efficacy, the primary endpoint was achieved in 31.3% of all patients, including 66.7% of those under preoperative treatment and 23.1% of those under chronic treatment. Sedation, anemia, and death were reported in 1 patient each as serious adverse drug reactions during the 24-week treatment. Metyrosine was shown to be tolerated and to relieve symptoms by reducing excess catecholamine in PPGL patients under both preoperative and chronic treatment.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/tratamiento farmacológico , Antineoplásicos/uso terapéutico , Inhibidores Enzimáticos/uso terapéutico , Paraganglioma/tratamiento farmacológico , Feocromocitoma/tratamiento farmacológico , alfa-Metiltirosina/uso terapéutico , Adolescente , Neoplasias de las Glándulas Suprarrenales/patología , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/efectos adversos , Niño , Inhibidores Enzimáticos/efectos adversos , Femenino , Humanos , Japón , Masculino , Persona de Mediana Edad , Paraganglioma/patología , Feocromocitoma/patología , Resultado del Tratamiento , Adulto Joven , alfa-Metiltirosina/efectos adversosRESUMEN
(E)-methyl isoeugenol (MIE) is a natural food flavour that constitutes 93.7% of an essential oil from Pimenta pseudocaryophyllus leaf. The leaf extracts of this species are used as a calming agent. As a ubiquitous food additive, the application of MIE for treating mood disorders appears to be globally attractive. Hence, we sought to evaluate general pharmacological activities, anticonvulsant, anxiolytic and antidepressant effects and the possible mechanisms of MIE actions. Administration of MIE was carried out prior to the exposure of a male Swiss mice to general behavioural tests, barbiturate sleep, PTZ-induced convulsion, light dark box (LDB), elevated plus maze (EPM), wire hanging, open field (OF) and forced swimming test (FST). The involvement of monoamine system was studied by mice pretreatment with WAY100635 (antagonist of 5-HT1A), α-methyl-p-tyrosine (AMPT; depletor of catecholamine) or p-chlorophenylalanine (PCPA; depletor of serotonin storage). There was no record of neurotoxic effect or animal's death during the course of general pharmacological tests. MIE at 250 and 500 mg kg(-1) potentiated the hypnotic effect of sodium pentobarbital. However, MIE did not protect against PTZ-induced convulsion. Except for MIE at 500 mg kg(-1), parameters evaluated in the LDB, EPM and OF demonstrated an anxiolytic like property of MIE. This effect was blocked by WAY100635 pretreatment. MIE at 500 mg kg(-1) elicited a reduction in locomotor activity of the mice in the OF. Anti-immobility effect of MIE 250 mg kg(-1) in the FST suggested an antidepressive like property. Unlike AMPT, pretreatment with PCPA reversed the antidepressant like effect of MIE. Our findings demonstrated anxiolytic and antidepressant like properties of (E)-methyl isoeugenol and suggested the participation of serotonergic pathways.
Asunto(s)
Anisoles/farmacología , Ansiolíticos/farmacología , Antidepresivos/farmacología , Aromatizantes/farmacología , Extractos Vegetales/farmacología , Animales , Relación Dosis-Respuesta a Droga , Fenclonina/efectos adversos , Masculino , Ratones , Condicionamiento Físico Animal , Piperazinas/efectos adversos , Piridinas/efectos adversos , Serotonina/sangre , Antagonistas de la Serotonina/efectos adversos , alfa-Metiltirosina/efectos adversosRESUMEN
Using positron emission tomography (PET) and an acute dopamine depletion challenge it is possible to estimate endogenous dopamine levels occupying dopamine D2/3 receptors (D2/3R) in humans in vivo. Our group has developed [(11)C]-(+)-PHNO, the first agonist radiotracer with preferential in vivo affinity for D3R. Thus, the use of [(11)C]-(+)-PHNO offers the novel possibility of (i) estimating in vivo endogenous dopamine levels at D2/3R using an agonist radiotracer, and (ii) estimating endogenous dopamine levels at D3R in extrastriatal regions such as the substantia nigra, hypothalamus, and ventral pallidum. Ten healthy participants underwent a [(11)C]-(+)-PHNO PET scan under baseline conditions and another under acute endogenous dopamine depletion achieved via oral administration of alpha-methyl-para-tyrosine (64 mg/kg). [(11)C]-(+)-PHNO binding was sensitive to acute dopamine depletion, allowing in vivo estimates of endogenous dopamine in D2R-rich regions (caudate and putamen), mixed D2/3R-rich regions (ventral striatum and globus pallidus), and extrastriatal D3R-rich regions (hypothalamus and ventral pallidum). Dopamine depletion decreased self-reported vigor, which was correlated with the reduction in dopamine levels in the globus pallidus. [(11)C]-(+)-PHNO is a suitable radiotracer for use in estimating endogenous dopamine levels at D2R and D3R in neuropsychiatric populations.
Asunto(s)
Encéfalo/diagnóstico por imagen , Dopamina/metabolismo , Oxazinas , Radiofármacos , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/metabolismo , Adulto , Afecto/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Dopaminérgicos/efectos adversos , Dopaminérgicos/sangre , Dopaminérgicos/farmacología , Femenino , Ácido Homovanílico/sangre , Humanos , Masculino , Metoxihidroxifenilglicol/sangre , Tomografía de Emisión de Positrones/métodos , Receptores de Dopamina D2/agonistas , Receptores de Dopamina D3/agonistas , alfa-Metiltirosina/efectos adversos , alfa-Metiltirosina/sangre , alfa-Metiltirosina/farmacologíaRESUMEN
Altered striatal dopaminergic neurotransmission is thought to be fundamental to schizophrenia. Increased presynaptic dopaminergic activity ([18F]-DOPA PET) may predate the onset of psychotic symptoms and correlates to clinical symptoms in subjects at Ultra High Risk (UHR) for developing psychosis. Postsynaptic dopaminergic neurotransmission has not been investigated yet in UHR patients. We hypothesized that synaptic dopamine concentration would be increased in UHR patients, and that synaptic dopamine concentration would be related to symptom severity. 14 UHR patients and 15 age and IQ matched controls completed an [123I]-IBZM SPECT scan at baseline and again after dopamine depletion with alpha-methyl-para-tyrosine (AMPT). We measured changes in radiotracer binding potential, compared these between UHR patients and controls, and correlated these to symptom severity. The UHR group as a whole did not differ significantly from controls. AMPT significantly reduced symptom severity in the UHR group (p=0.014). Higher synaptic dopamine concentration predicted larger reduction of positive symptoms following depletion in the UHR group (p=0.01). In UHR patients, positive symptoms responded to dopamine depletion, comparable to observations in schizophrenia, suggesting a similar mechanism. Higher synaptic dopamine concentration was associated with more severe positive symptoms and a greater reduction of these symptoms following depletion.
Asunto(s)
Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Neuroimagen Funcional/psicología , Trastornos Psicóticos/metabolismo , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D3/metabolismo , Adulto , Benzamidas , Estudios de Casos y Controles , Cuerpo Estriado/efectos de los fármacos , Dopamina/orina , Antagonistas de Dopamina , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/metabolismo , Femenino , Ácido Homovanílico/sangre , Humanos , Masculino , Prolactina/sangre , Trastornos Psicóticos/sangre , Trastornos Psicóticos/diagnóstico , Trastornos Psicóticos/orina , Pirrolidinas , Ensayo de Unión Radioligante/métodos , Tirosina 3-Monooxigenasa/antagonistas & inhibidores , alfa-Metiltirosina/efectos adversos , alfa-Metiltirosina/sangre , alfa-Metiltirosina/farmacologíaRESUMEN
PURPOSE: Acute monoamine depletion paradigms using alpha-methyl-para-tyrosine (AMPT) combined with single photon emission computed tomography (SPECT) have been used successfully to evaluate disturbances in central dopaminergic neurotransmission. However, severe side effects due to relatively high doses (4,500 to 8,000 mg) of AMPT have been reasons for study withdrawal. Thus, we assessed the effectiveness and tolerability of two alternative procedures, using lower doses of AMPT. METHODS: Six healthy subjects underwent three measurements of striatal dopamine D(2) receptor (D(2)R)-binding potential (BP(ND)) with SPECT and the selective radiolabeled D(2)R antagonist [(123)I]IBZM. All subjects were scanned in the absence of pharmacological intervention (baseline) and after two different depletion procedures. In the first depletion session, over 6 h, subjects were administered 1,500 mg of AMPT before scanning. In the second depletion session, over 25 h, subjects were administered 40 mg AMPT/kg body weight. We also administered the Subjective Well-being Under Neuroleptic Treatment Scale, a self-report instrument designed to measure the subjective experience of patients on neuroleptic medication. RESULTS: We found no change of mean D(2)R BP(ND) after the first and short AMPT challenge compared to the baseline. However, we found a significant increase in striatal D(2)R BP(ND) binding after the AMPT challenge adjusted for bodyweight compared to both other regimen. Although subjective well-being worsened after the prolonged AMPT challenge, no severe side effects were reported. CONCLUSIONS: Our results imply a low-dosage, suitable alternative to the common AMPT procedure. The probability of side effects and study withdrawal can be reduced by this procedure.
Asunto(s)
Benzamidas , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Dopamina/metabolismo , Radioisótopos de Yodo , Pirrolidinas , Tomografía Computarizada de Emisión de Fotón Único/métodos , alfa-Metiltirosina , Adulto , Cuerpo Estriado/diagnóstico por imagen , Cuerpo Estriado/metabolismo , Tolerancia a Medicamentos , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/efectos adversos , Femenino , Humanos , Masculino , Prolactina/sangre , Radiofármacos , Receptores de Dopamina D2/agonistas , Receptores de Dopamina D2/metabolismo , Transmisión Sináptica , alfa-Metiltirosina/administración & dosificación , alfa-Metiltirosina/efectos adversosRESUMEN
AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.
Asunto(s)
Discinesia Inducida por Medicamentos/tratamiento farmacológico , Distonía/tratamiento farmacológico , Inhibidores Enzimáticos/uso terapéutico , alfa-Metiltirosina/uso terapéutico , Adolescente , Adulto , Lesiones Encefálicas/complicaciones , Dopamina/fisiología , Inhibidores Enzimáticos/efectos adversos , Femenino , Humanos , Fosforilación , Temblor/tratamiento farmacológico , Temblor/etiología , Tirosina 3-Monooxigenasa/antagonistas & inhibidores , alfa-Metiltirosina/efectos adversosRESUMEN
Dysphoria is an integral part of the symptomatology of a variety of clinical states, though there is little empirical data available on the qualitative and quantitative aspects of this phenomenon. The purpose of the study was to administer alphamethyl paratyrosine (AMPT), a catecholamine depleting agent as a chemical probe to induce dysphoria, and document the ensuing changes in mental status. AMPT (4-5 g/day) was administered to a group of medication-free schizophrenic patients (n=13) over a 48 hour period, and changes in their mental status were monitored at 12 hour intervals with the Profile of Mood States (POMS), Addiction Research Center Inventory (ARCI), Drug Attitude Inventory (DAI) and other standardized rating scales. All of the subjects experienced dysphoric responses of variable severity. The profile of changes included blunted pleasure responsivity, clouded thinking, loss of motivation and lowered vigilance. Subtle subjective changes were experienced soon after the first dose of AMPT and the dysphoria steadily worsened, resulting in social withdrawal and personal distress. Subjective responses were the earliest to manifest, followed by akathisia, akinesia and rigidity. We conclude that AMPT induced dopamine depletion is a safe, rapid, reliable and reversible method of studying dysphoric states in humans. The technique is helpful in examining the phenomenology of dysphoria, the temporal relationship between subjective and behavioural consequences of dopamine depletion, and the role of dopamine in mediating subtle aspects of pleasure responsivity, which is in turn crucial to the understanding of treatment non-adherence in schizophrenia and the origins of comorbid substance abuse.
Asunto(s)
Cuerpo Estriado , Inhibidores Enzimáticos/efectos adversos , Esquizofrenia/metabolismo , Esquizofrenia/patología , Tomografía Computarizada de Emisión de Fotón Único , alfa-Metiltirosina/efectos adversos , Adulto , Catecolaminas/antagonistas & inhibidores , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/metabolismo , Cuerpo Estriado/patología , Dopamina/metabolismo , Antagonistas de Dopamina/efectos adversos , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Trastornos del Humor/inducido químicamente , Esquizofrenia/diagnóstico , Factores de TiempoAsunto(s)
Cuerpo Estriado/efectos de los fármacos , Dopamina/deficiencia , Dopamina/fisiología , Inhibidores Enzimáticos/efectos adversos , Trastornos Mentales/inducido químicamente , Receptores de Dopamina D2/efectos de los fármacos , alfa-Metiltirosina/efectos adversos , Adulto , Benzamidas , Cuerpo Estriado/diagnóstico por imagen , Cuerpo Estriado/metabolismo , Inhibidores Enzimáticos/farmacología , Humanos , Radioisótopos de Yodo , Masculino , Trastornos Mentales/prevención & control , Trastornos Mentales/psicología , Pirrolidinas , Receptores de Dopamina D2/deficiencia , Receptores de Dopamina D2/metabolismo , Proyectos de Investigación/normas , Tomografía Computarizada de Emisión de Fotón Único/métodos , alfa-Metiltirosina/farmacologíaRESUMEN
Recent positron emission tomography (PET) studies have assessed the level of dopamine (DA) D1 receptors in the prefrontal cortex (PFC) in patients with schizophrenia and have generated contradictory findings. In the PFC of patients with schizophrenia, the binding potential (BP) of [11C]NNC 112 has been reported as increased, while the BP of [11C]SCH 23390 was reported as decreased or unchanged. In this study, the effect of acute and subchronic DA depletion on the in vivo binding of [11C]NNC 112 and [3H]SCH 23390 was evaluated in rats. Acute DA depletion did not affect [11C]NNC 112 in vivo binding, but paradoxically decreased [3H]SCH 23390 in vivo binding. Subchronic DA depletion was associated with increased [11C]NNC 112 in vivo binding and decreased [3H]SCH 23390 in vivo binding. Together, these data demonstrate that the in vivo binding of these radiotracers is differentially affected by changes in endogenous DA tone, and suggest that alterations in the binding of these tracers in the PFC of patients with schizophrenia might reflect changes in D1 receptors secondary to sustained deficit in prefrontal DA function.
Asunto(s)
Benzazepinas/farmacocinética , Benzofuranos/farmacocinética , Antagonistas de Dopamina/farmacocinética , Dopamina/metabolismo , Receptores de Dopamina D1/metabolismo , Esquizofrenia/metabolismo , Inhibidores de Captación Adrenérgica/efectos adversos , Animales , Sitios de Unión , Radioisótopos de Carbono , Cromatografía Líquida de Alta Presión , Cuerpo Estriado/metabolismo , Modelos Animales de Enfermedad , Dopamina/deficiencia , Inhibidores Enzimáticos/efectos adversos , Hipocampo/metabolismo , Masculino , Corteza Prefrontal/metabolismo , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Receptores de Dopamina D1/efectos de los fármacos , Reserpina/efectos adversos , Esquizofrenia/inducido químicamente , Factores de Tiempo , Tritio , alfa-Metiltirosina/efectos adversosRESUMEN
Dopamine receptor agonists provide symptomatic relief in the early stages of Parkinson's disease, but with disease progression, their efficacy decreases. The reason behind this decrease in effectiveness is unknown, but maximal efficacy may be dependent on endogenous dopaminergic tone to provide stimulation of D1 and D2 receptor subtypes. Therefore, we have investigated the effects of the tyrosine hydroxylase inhibitor alpha-methyl-p-tyrosine (AMPT) on the actions of D1, D2, and D1/D2 agonists and levodopa (L-dopa) in common marmosets treated with 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Administration of AMPT alone further increased motor disability and decreased locomotor activity. Administration of L-dopa reversed motor disability and increased locomotor activity, and this reversal was not affected by previous AMPT treatment. The D1 agonist A-77636 and the D2 agonist quinpirole reversed motor deficits, but these effects were markedly inhibited by previous AMPT treatment. Administration of quinpirole with A-77636 produced a reversal of motor deficits that was more resistant to AMPT pretreatment than was the effect produced by quinpirole or A-77636 alone. These data suggest that D1 and D2 receptor stimulation are required for dopamine receptor agonists to produce a maximal antiparkinsonian response. The reversal of motor deficits produced by the mixed D1/D2 agonist apomorphine was more resistant to AMPT treatment than that produced by quinpirole or A-77636. However, the motor effects of A-77636 plus quinpirole and of apomorphine were still affected by AMPT treatment. This suggests that loss of tyrosine hydroxylase activity may also alter motor activity through inhibition of endogenous L-dopa or norepinephrine synthesis, because both are also involved in the genesis of motor activity.
Asunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/efectos adversos , Antiparkinsonianos/farmacología , Dopaminérgicos/farmacología , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Discinesia Inducida por Medicamentos/fisiopatología , Inhibidores Enzimáticos/efectos adversos , Levodopa/farmacología , Locomoción/efectos de los fármacos , Receptores de Dopamina D1/efectos de los fármacos , Receptores de Dopamina D2/efectos de los fármacos , Tirosina 3-Monooxigenasa/antagonistas & inhibidores , alfa-Metiltirosina/efectos adversos , Adamantano/análogos & derivados , Adamantano/farmacología , Animales , Apomorfina/farmacología , Benzopiranos/farmacología , Callithrix , Dopaminérgicos/efectos adversos , Agonistas de Dopamina/farmacología , Femenino , Levodopa/metabolismo , Masculino , Quinpirol/farmacología , Receptores de Dopamina D1/agonistas , Receptores de Dopamina D2/agonistasRESUMEN
The aim of the present study was to assess the efficacy of pramipexole (2-amino-4,5,6, 7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochloride), a new dopamine D(2)/D(3) receptor agonist, to attenuate parkinsonian-like muscle rigidity in rats. Muscle tone was examined using a combined mechano- and electromyographic (EMG) method, which simultaneously measured the muscle resistance of a rat's hindlimb to passive extension and flexion at the ankle joint, and the EMG acitivity of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior. Muscle rigidity was produced by reserpine (5 mg/kg) injected in combination with alpha-methyl-p-tyrosine (250 mg/kg) or by haloperidol (0.5 mg/kg). Pramipexole in doses of 0.5-5 mg/kg antagonized both reserpine+alpha-methyl-p-tyrosine- and haloperidol-induced muscle rigidity. Pramipexole also reduced reserpine-enhanced tonic and reflex EMG activities in the gastrocnemius muscle. The present results suggest that stimulation of the postsynaptic dopamine receptor may be chiefly responsible for the antiparkinsonian action of pramipexole. The ability of pramipexole to diminish the parkinsonian-like muscle rigidity seems to indicate a therapeutic value of this compound in the treatment of Parkinson's disease.
Asunto(s)
Agonistas de Dopamina/farmacología , Rigidez Muscular/tratamiento farmacológico , Enfermedad de Parkinson Secundaria/tratamiento farmacológico , Tiazoles/farmacología , Animales , Benzotiazoles , Relación Dosis-Respuesta a Droga , Electromiografía/efectos de los fármacos , Haloperidol/efectos adversos , Masculino , Rigidez Muscular/inducido químicamente , Rigidez Muscular/fisiopatología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/fisiopatología , Enfermedad de Parkinson Secundaria/inducido químicamente , Enfermedad de Parkinson Secundaria/fisiopatología , Pramipexol , Ratas , Ratas Wistar , Reserpina/efectos adversos , Resultado del Tratamiento , alfa-Metiltirosina/efectos adversosRESUMEN
Because it is a competitive inhibitor of tyrosine hydroxylase, alpha-methyl-para-tyrosine (AMPT) is used to study psychiatric disorders. Melatonin serves as a biological marker of catecholamine function since its secretion is regulated by noradrenergic neurons via beta-adrenergic receptors in the pineal gland. Ten healthy volunteers were administered AMPT in a double-blind placebo controlled study. When subjects received AMPT, nocturnal 6-hydroxymelatonin sulfate (6-SM) decreased significantly as compared with promethazine (night 1 P=0.002; and night 2 P=0.001). Urinary MHPG also decreased on both study days (DF1,9 F=9.82, GG=0.0121). Nocturnal 6-SM excretion and melatonin secretion correlated highly (r=0.91, P=0.0007). Behavioral ratings did not reveal a difference in symptomatology and did not correlate with changes in 6-SM or MHPG. This study demonstrates in healthy controls that 6-SM reliably reflects presynaptic catecholamine depletion induced by AMPT without the emergence of behavioral symptoms.